Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity
Article first published online: 14 MAY 2013
Copyright © 2013 American Cancer Society
Volume 119, Issue 16, pages 3076–3083, 15 August 2013
How to Cite
Patel, C., Stenke, L., Varma, S., Lindberg, M. L., Björkholm, M., Sjöberg, J., Viktorsson, K., Lewensohn, R., Landgren, O., Gottesman, M. M. and Gillet, J.-P. (2013), Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity. Cancer, 119: 3076–3083. doi: 10.1002/cncr.28098
- Issue published online: 2 AUG 2013
- Article first published online: 14 MAY 2013
- Manuscript Accepted: 4 MAR 2013
- Manuscript Received: 8 FEB 2013
- acute myeloid leukemia;
- acquired drug resistance;
- therapy-related drug resistance;
- multidrug resistance;
- leukemia cell lines
Studies of mechanisms mediating resistance to chemotherapy led to the discovery of the multidrug transporter ABCB1 (ATP-binding cassette, subfamily B, member 1), often expressed in leukemic cells of patients with acute myeloid leukemia (AML). Most clinical trials evaluating the strategy of inhibiting efflux-mediated chemotherapeutic resistance have been unsuccessful, clearly indicating the need for a better approach.
This study investigated the clinical relevance of 380 genes whose expression has been shown to affect the response to chemotherapy, mostly through in vitro studies, in 11 paired samples obtained at AML diagnosis and at relapse. The expression profiling of these 380 genes was performed using TaqMan-based quantitative reverse-transcription polymerase chain reaction. Patients had a median age of 58 years at diagnosis, a median duration of complete remission of 284.5 days, and a median overall survival of 563 days. Cytogenetic abnormalities were detected at diagnosis in 4 patients, whereas 5 displayed a normal karyotype and 2 were not investigated.
Hierarchical clustering shows that samples taken at diagnosis and relapse clustered in pairs for 6 patients of the 11 studied, suggesting recurrence of the same leukemic blast, whereas for the other 5 patients, the data indicate their relapse blasts arose from different origins. A patient-by-patient analysis of the paired samples led to the striking observation that each had a unique gene signature representing different mechanisms of resistance.
The data underline the need for personalized molecular analysis to tailor treatment for patients with AML. Cancer 2013;119:3076—3083. © 2013 American Cancer Society.